Chemotherapy Outcomes Among Pediatric Cancer Patients with Active COVID-19 Infection in a Tertiary Hospital

Clicks: 12
ID: 327264
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #118 of 147 articles by views in journal of the pediatric infectious diseases society

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 147 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background The impact of COVID-19 on pediatric cancer patients undergoing chemotherapy remains a significant concern due to their immunocompromised state. Balancing the risks of chemotherapy-induced immunosuppression against the dangers of delaying cancer treatment is a critical challenge, with limited evidence to guide practice. Objective This study aimed to describe the clinico-demographic characteristics and determine the post-chemotherapy outcomes of pediatric cancer patients with active COVID-19 infection. Methods A retrospective, cross-sectional study was conducted on 34 pediatric cancer patients with RT-PCR-confirmed COVID-19 who received chemotherapy between July 2020 and December 2023 at a government tertiary hospital. Data on demographics, cancer profile, clinical presentation, diagnostic parameters, and outcomes (discharge status, febrile neutropenia, ICU admission, length of stay, etc.) were collected and analyzed using descriptive statistics and association tests. Results The cohort was predominantly male (76.5%), aged 1-5 years (35.3%), with hematologic malignancies (60%). Most patients had asymptomatic (35.3%) or mild (44.1%) COVID-19. Febrile neutropenia occurred in 34.3% of cases. The overall mortality rate was low (2.9%), with one non-COVID-related death. ICU admission was required in 5.9% of cases, all with severe COVID-19. Disease severity was significantly associated with febrile neutropenia (p=0.000) and nosocomial infection (p=0.005). Absolute neutrophil count (ANC) was significantly associated with ICU admission (p=0.001). Most patients (97.1%) were discharged alive. Conclusion Pediatric cancer patients with COVID-19, particularly those with mild or asymptomatic infection, can continue chemotherapy with favorable outcomes. Disease severity and elevated ANC are significant predictors of complications. These findings support the individualized continuation of cancer therapy during active infection. Further prospective studies are recommended to establish standardized guidelines.
Reference Key
openalex_W7204624975 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Meg B Tuazon, Mary Crist D Jamora
Are you one of these authors? Claim your profile
Journal journal of the pediatric infectious diseases society
Year 2026
DOI
10.1093/jpids/piag070/piag070.061
URL
https://academic.oup.com/jpids/article-pdf/15/Supplement_2/S26/70833366/piag070.061.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.